SELLAS Life Sciences (SLS) Net Cash Flow (2010 - 2026)

SELLAS Life Sciences (SLS) has 17 years of Net Cash Flow data on file, last reported at $35.4 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at $35.4 million, up 143.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $78.7 million (up 688.77% YoY), and the FY2025 annual result was $57.9 million, up 409.83% from the prior year.
• Net Cash Flow improved to $35.4 million in Q1 2026 per SLS's latest filing, from $27.5 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $35.4 million in Q1 2026 and troughed at -$9.8 million in Q3 2023.
• A 5-year average of $5.5 million and a median of -$1.4 million in 2023 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2024: Net Cash Flow surged 814.81% in 2022, then plunged 396.53% in 2024.
• A 5-year view of Net Cash Flow shows it stood at -$4.2 million in 2022, then soared by 65.92% to -$1.4 million in 2023, then slumped by 396.53% to -$7.1 million in 2024, then jumped by 484.8% to $27.5 million in 2025, then rose by 28.57% to $35.4 million in 2026.
• Business Quant data shows SLS's Net Cash Flow at $35.4 million in Q1 2026, $27.5 million in Q4 2025, and $19.0 million in Q3 2025.